- South Korea
- /
- Biotech
- /
- KOSDAQ:A196170
Top KRX Growth Stocks With Insider Ownership In October 2024
Reviewed by Simply Wall St
In recent months, South Korea's economy has shown resilience with a notable current account surplus, supported by robust export growth despite a slight decline from July to August. In this context of economic activity, companies with strong insider ownership often attract attention as they can indicate confidence in the firm's potential for sustained growth and alignment of interests between management and shareholders.
Top 10 Growth Companies With High Insider Ownership In South Korea
Name | Insider Ownership | Earnings Growth |
People & Technology (KOSDAQ:A137400) | 16.4% | 35.6% |
Seojin SystemLtd (KOSDAQ:A178320) | 30.8% | 49.1% |
Bioneer (KOSDAQ:A064550) | 15.8% | 97.6% |
Oscotec (KOSDAQ:A039200) | 26.1% | 122% |
Vuno (KOSDAQ:A338220) | 19.5% | 110.9% |
HANA Micron (KOSDAQ:A067310) | 18.3% | 100.3% |
Park Systems (KOSDAQ:A140860) | 33% | 34.6% |
UTI (KOSDAQ:A179900) | 33.1% | 134.6% |
Techwing (KOSDAQ:A089030) | 18.7% | 83.6% |
INTEKPLUS (KOSDAQ:A064290) | 16.3% | 96.7% |
Let's review some notable picks from our screened stocks.
ALTEOGEN (KOSDAQ:A196170)
Simply Wall St Growth Rating: ★★★★★★
Overview: ALTEOGEN Inc. is a biotechnology company specializing in the development of long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars, with a market cap of ₩19.60 trillion.
Operations: The company's revenue primarily comes from its biotechnology segment, totaling ₩90.79 billion.
Insider Ownership: 26.6%
Earnings Growth Forecast: 99.5% p.a.
ALTEOGEN is forecast to achieve substantial growth, with revenue expected to increase by 64.2% annually, outpacing the South Korean market's average of 10.5%. The company is projected to become profitable within three years and has a very high forecasted return on equity of 66.3%. Despite past shareholder dilution, it currently trades at a significant discount to its estimated fair value, suggesting potential undervaluation in the market.
- Click here and access our complete growth analysis report to understand the dynamics of ALTEOGEN.
- Insights from our recent valuation report point to the potential overvaluation of ALTEOGEN shares in the market.
Enchem (KOSDAQ:A348370)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Enchem Co., Ltd. manufactures and sells electrolytes and additives for secondary batteries and EDLC, with a market cap of ₩4.24 trillion.
Operations: The company generates revenue of ₩348.75 billion from its Electronic Components & Parts segment.
Insider Ownership: 19.4%
Earnings Growth Forecast: 155.2% p.a.
Enchem is projected to achieve significant growth, with revenue expected to rise by 63% annually, surpassing the South Korean market's average of 10.5%. The company is forecasted to become profitable within three years, indicating above-average market growth potential. Despite recent shareholder dilution and high share price volatility over the past three months, Enchem's robust earnings growth forecast of 155.2% per year highlights its potential as a dynamic investment opportunity in South Korea.
- Unlock comprehensive insights into our analysis of Enchem stock in this growth report.
- Upon reviewing our latest valuation report, Enchem's share price might be too optimistic.
HYBE (KOSE:A352820)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: HYBE Co., Ltd. operates in music production, publishing, and artist development and management, with a market cap of ₩7.45 trillion.
Operations: The company's revenue is primarily derived from its Label segment at ₩1.28 trillion, followed by the Solution segment at ₩1.24 trillion, and the Platform segment contributing ₩361.12 billion.
Insider Ownership: 32.5%
Earnings Growth Forecast: 42.2% p.a.
HYBE's earnings are forecast to grow significantly at 42.23% annually, outpacing the South Korean market's average growth. Despite recent challenges in net income, the company trades below its estimated fair value and analysts expect a stock price increase of 43.4%. A recent share buyback program aimed at stabilizing stock prices involved repurchasing shares worth KRW 26.09 billion, reflecting strategic financial management amidst fluctuating earnings results.
- Dive into the specifics of HYBE here with our thorough growth forecast report.
- Upon reviewing our latest valuation report, HYBE's share price might be too pessimistic.
Make It Happen
- Gain an insight into the universe of 85 Fast Growing KRX Companies With High Insider Ownership by clicking here.
- Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance.
- Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets.
Seeking Other Investments?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About KOSDAQ:A196170
ALTEOGEN
A bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars.
Exceptional growth potential with excellent balance sheet.